Perospirone (SM-9018 free base): Atomic Facts for Schizophrenia Research

Executive Summary: Perospirone (SM-9018 free base) is an orally active atypical antipsychotic agent designed for schizophrenia research, with well-characterized receptor affinities for 5-HT2A (0.6 nM), D2 (1.4 nM), and 5-HT1A (2.9 nM) receptors [ApexBio]. It demonstrates concentration-dependent inhibition of vascular Kv1.5 channels, with an IC50 of 20.54 ± 2.89 μM, suggesting a notable off-target effect (Mun et al., 2025). The compound is supplied as a solid (C23H30N4O2S, MW 426.57) and is for research use only; long-term storage of its DMSO solution is not recommended. Perospirone’s multi-receptor and ion channel modulatory actions provide mechanistic insight for neuropsychiatric and vascular models. Its safety and efficacy profile is well established in Japan but remains underexplored elsewhere (Mun et al., 2025).

Biological Rationale

Schizophrenia is characterized by dysregulation of dopaminergic and serotonergic signaling pathways. Atypical antipsychotic agents, such as Perospirone (SM-9018 free base), act on both dopamine and serotonin receptors, addressing positive and negative symptoms (Mun et al., 2025). The dual antagonism at 5-HT2A and D2 receptors is the cornerstone of the serotonin–dopamine antagonist (SDA) class. Partial agonism at the 5-HT1A receptor further modulates neurotransmitter release and may reduce extrapyramidal symptoms compared to typical antipsychotics [Related: Mechanisms, Receptor Profile]. Recent studies highlight additional, off-target actions on vascular ion channels, potentially impacting cardiovascular physiology (Mun et al., 2025).

Mechanism of Action of Perospirone (SM-9018 free base)

Perospirone is a potent 5-HT2A receptor antagonist (Ki = 0.6 nM) and D2 receptor antagonist (Ki = 1.4 nM), with partial agonist activity at 5-HT1A receptors (Ki = 2.9 nM) [Product Page]. These actions modulate serotonergic and dopaminergic neurotransmission. 5-HT2A antagonism increases dopamine release in the mesocortical pathway, improving negative symptoms. D2 antagonism alleviates positive symptoms by reducing dopamine signaling in the mesolimbic pathway. Partial 5-HT1A agonism may enhance efficacy and tolerability by further modulating neurotransmitter systems. Beyond receptor activity, Perospirone inhibits vascular Kv1.5 channels (IC50 = 20.54 μM), which may influence vascular tone and membrane potential (Mun et al., 2025). This multi-target profile supports research into neuropsychiatric disorder models and cardiovascular effects [Related: Mechanisms and Innovation].

Evidence & Benchmarks

• Perospirone (SM-9018 free base) antagonizes the serotonin 5-HT2A receptor with a binding affinity (Ki) of 0.6 nM, supporting its classification as a high-affinity SDA [Product Page].
• It blocks dopamine D2 receptors with a binding affinity (Ki) of 1.4 nM, effectively modulating dopaminergic signaling [Product Page].
• Perospirone is a partial agonist at 5-HT1A receptors (Ki = 2.9 nM), potentially reducing extrapyramidal side effects [Related: Mechanisms, Receptor Profile].
• It inhibits vascular voltage-gated Kv1.5 potassium channels with an IC50 of 20.54 ± 2.89 μM, in a concentration-dependent but use-independent manner (Mun et al., 2025).
• Pretreatment with the Kv1.5 inhibitor DPO-1 attenuates Perospirone-induced Kv current inhibition, confirming Kv1.5 as a primary target within vascular smooth muscle cells (Mun et al., 2025).
• Perospirone is stable as a solid at -20°C; DMSO solutions should be freshly prepared, as long-term storage is not recommended [Product Page].
• Its use is restricted to research; it is not approved for diagnostic or therapeutic medical applications outside Japan (Mun et al., 2025).

Applications, Limits & Misconceptions

Perospirone (SM-9018 free base) is primarily employed in preclinical models of schizophrenia and related neuropsychiatric disorders. Its multi-receptor activity allows mechanistic dissection of serotonergic and dopaminergic pathways. The recent discovery of Kv1.5 channel inhibition positions Perospirone as a tool for investigating vascular K+ channel physiology [Related: Charting New Territory]. This article extends prior reviews by supplying atomic, up-to-date benchmarks and highlighting cardiovascular off-targets not emphasized elsewhere.

Common Pitfalls or Misconceptions

• Not a clinical therapy outside Japan: Perospirone is not approved for clinical use in most countries; it is for research only (Mun et al., 2025).
• Long-term DMSO solution storage: DMSO solutions of Perospirone are unstable; always prepare fresh aliquots for experiments [Product Page].
• Limited receptor coverage: Perospirone does not antagonize all dopamine or serotonin receptor subtypes; its selectivity profile should be considered in experimental design [Related: Mechanisms, Receptor Profile].
• Off-target vascular effects: The Kv1.5 channel inhibition may confound results in cardiovascular or metabolic studies (Mun et al., 2025).
• Not a general K+ channel blocker: Perospirone’s inhibitory effects are specific to Kv1.5 channels and do not broadly affect all K+ channel subtypes (Mun et al., 2025).

Workflow Integration & Parameters

Preparation: Perospirone is supplied as a solid (C23H30N4O2S, MW 426.57) and is typically dissolved in DMSO to a 10 mM stock concentration. For stability, store the solid at -20°C. Avoid long-term storage of DMSO solutions; prepare aliquots immediately before use [Perospirone (SM-9018 free base) BA5009 kit]. Shipments are on Blue Ice (small molecules) or Dry Ice (modified nucleotides).

Experimental Use: Typical working concentrations for in vitro receptor binding or functional assays range from 1 nM to 50 μM, depending on target. Kv1.5 inhibition is observed at micromolar concentrations (IC50 ~20 μM). Use in animal models should be guided by published pharmacokinetic data and ethical standards.

Researchers seeking mechanistic depth may consult this article, which reviews troubleshooting and advanced workflows for Perospirone. This current review updates the mechanistic landscape by adding evidence for off-target Kv1.5 channel modulation.

Conclusion & Outlook

Perospirone (SM-9018 free base) is a robust tool for schizophrenia and neuropsychiatric disorder research. Its high-affinity 5-HT2A and D2 antagonism, partial 5-HT1A agonism, and newly recognized Kv1.5 inhibition provide multiple mechanistic entry points for experimental models. Researchers should consider its off-target vascular actions when designing experiments, especially in cardiovascular contexts. For detailed technical information and purchasing, visit the Perospirone (SM-9018 free base) BA5009 page. Future research may clarify further off-targets and expand translational relevance outside Japan.